Elevated baseline levels of tumor-infiltrating lymphocytes (TILs) have been correlated with higher rates of pCR in HER2-positive breast cancer patients undergoing neoadjuvant HER2-targeted therapy. The gene discussed is ERBB2; the disease is breast carcinoma.